Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| HUM00167104 | Other Identifier | University of Michigan | |
| UM-FHPG-03 | Other Identifier | University of Michigan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this exploratory study is to test whether [18F]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of [18F]3F-PHPG as a clinical tool for neuroendocrine tumor localization and staging.
Subjects enrolled in this study will be recruited from the population of adult patients with neuroendocrine tumors, including pheochromocytoma and paraganglioma, being treated at the University of Michigan Hospital.
The primary objective of the study is to obtain basic information on the biodistribution and pharmacokinetics of [18F]3F-PHPG in cancer patients with neuroendocrine tumors.
The secondary objective of the study is to compare the diagnostic performance of [18F]3F-PHPG in cancer patients with neuroendocrine tumors with the FDA approved radiopharmaceuticals [123I]metaiodobenzylguanidine ([123I]MIBG) and [68Ga]DOTA-TATE in the same patients. A group of approximately 12 of the subjects scanned with [18F]3F-PHPG will be recruited to undergo a whole-body [123I]MIBG scan using planar scintigraphy with a gamma camera, following the standard clinical protocol used at the University of Michigan. In addition, a single SPECT/CT scan of the primary neuroendocrine tumor will be acquired after the whole-body scan to provide a tomographic image for comparison with the positron emission tomography (PET) image acquired using [18F]3F-PHPG. Several subjects enrolled on this study will undergo [68Ga]DOTA-TATE scans off-study, as part of routine clinical management. Existing [68Ga]DOTA-TATE scans will be obtained from consenting subjects' medical records.
This is an exploratory study and thus all statistical data analyses will be exploratory in nature.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PET/CT scan with radiotracer [18F]3F-PHPG | Experimental | Novel radiotracer [18F]3F-PHPG prior to whole-body PET/CT scan. |
|
| Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG | Active Comparator | FDA approved radiotracer [123I]MIBG prior to whole-body planar scintigraphy and SPECT/CT scan (standard clinical imaging procedures). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 3-[18F]Fluoro-para-hydroxyphenethylguanidine | Drug | Single IV injection of 12.0 mCi (+/- 10%) [18F]3F-PHPG |
|
| Measure | Description | Time Frame |
|---|---|---|
| Image quality assessed by standardized uptake values | The maximum standardized uptake value (SUVmax) of [18F]3F-PHPG in neoplastic lesions will be quantified from the PET images using region-of-interest (ROI) analysis. | Up to 180 minutes |
| Biodistribution of [18F]3F-PHPG | Changes in the measured tissue concentrations (kBq/cc) of [18F]3F-PHPG in neoplastic lesions and abdominal organs from the two acquired PET images (acquired at 90 min and 180 min after tracer injection). | 90 minutes and 180 minutes after administration of tracer |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Pregnancy or lactation
Claustrophobia
Inability to lie flat for 60 minutes
Currently taking medications that may alter PET scans of neuroendocrine tumors with these tracers, including any of the following:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Raffel, Ph.D. | University of Michigan Rogel Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Michigan Rogel Cancer Center | Ann Arbor | Michigan | 48109 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
All subjects (30 anticipated) will receive a PET/CT scan using the novel radiotracer [18F]3F-PHPG as an imaging agent. Within 60 days after the [18F]3F-PHPG PET/CT scan, approximately 12 of the subjects will also receive an FDA approved radiotracer [123I]MIBG one day prior to whole-body planar scintigraphy and SPECT/CT scans. The [123I]MIBG scans are standard clinical imaging procedures.
Not provided
Not provided
Not provided
Not provided
|
| [123I] metaiodobenzylguanidine | Drug | Single IV injection of 10.0 mCi [123I]MIBG |
|
|
| Positron emission tomography/computed tomography scan | Diagnostic Test | Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of [18F]3F-PHPG |
|
|
| Planar scintigraphy scan | Diagnostic Test | Whole-body scan using planar scintigraphy with a gamma camera performed the day after IV injection of [123I]MIBG |
|
| Single photon emission computed tomography/computed tomography scan | Diagnostic Test | SPECT/CT scan of the primary neuroendocrine tumor performed the day after IV injection of [123I]MIBG |
|
|
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| ID | Term |
|---|---|
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
Not provided
Not provided
| ID | Term |
|---|---|
| C000614958 | Iodine-123 |
| D019797 | 3-Iodobenzylguanidine |
| D049268 | Positron-Emission Tomography |
| D014057 | Tomography, X-Ray Computed |
| D000072078 | Positron Emission Tomography Computed Tomography |
| D015899 | Tomography, Emission-Computed, Single-Photon |
| D000072098 | Single Photon Emission Computed Tomography Computed Tomography |
| ID | Term |
|---|---|
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
| D007462 | Iodobenzenes |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D006847 | Hydrocarbons, Iodinated |
| D006846 | Hydrocarbons, Halogenated |
| D014055 | Tomography, Emission-Computed |
| D007090 | Image Interpretation, Computer-Assisted |
| D003952 | Diagnostic Imaging |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D007089 | Image Enhancement |
| D010781 | Photography |
| D011877 | Radionuclide Imaging |
| D014054 | Tomography |
| D003947 | Diagnostic Techniques, Radioisotope |
| D011856 | Radiographic Image Enhancement |
| D011859 | Radiography |
| D014056 | Tomography, X-Ray |
| D064847 | Multimodal Imaging |
Not provided
Not provided